In a quest to anticipate and combat the latest healthcare challenges, infection prevention professionals battle numerous fronts involving COVID-19 patient care, sepsis diagnosis, and public health outbreaks. This article delves into the evolving COVID-19 therapy protocols, significant developments in sepsis testing, and proactively managing public health outbreaks.
A recent discussion during a COVID-19 Therapies roundtable highlighted the continued evolution of treatment options for inpatient COVID-19 victims. The panel of experts focused on mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and Remdesivir in the treatment of severe cases. Despite a marked decrease in hospitalizations since the pandemic’s onset, intermittent waves of acute cases necessitate advanced interventions. While ECMO usage soared during the limited treatment options phase, the therapy continues to benefit specific COVID-19 afflicted individuals. Concurrently, the antiviral therapy, Remdesivir, has become an integral part of severe inpatient treatment, contributing significantly to reducing mortality.
The next significant step in healthcare is the introduction of MeMed’s MeMed Severity test, a rapid diagnostic tool with a breakthrough device designation (BDD) from the FDA. This diagnostic tool is poised to revolutionize sepsis management using host-response technology and machine learning to assess acute infection patients’ risk of critical outcomes. Targeting a gap in sepsis diagnosis, the test provides valuable insights into high-risk patients within 15 minutes, thereby enhancing triage and treatment decisions.
The Infection Prevention in Practice study underscores the need for more research into the impact of drug-resistant organisms like Vancomycin-resistant enterococci (VRE) on sepsis outcomes. Given a 7% higher mortality rate in VRE colonized patients, the study focuses on the necessity of proactively identifying colonization to mitigate more severe outcomes.
Another study in JAMA Network emphasizing the heightened prevalence of Hepatitis C virus (HCV) among Madrid’s homeless population underscores the need for targeted intervention. Key risk factors identified include injection drug use, lack of financial income, and alcohol misuse. Reducing HCV infection rates in at-risk groups mandates the development of targeted prevention policies and robust support systems.
Lastly, an E coli O157:H7 outbreak tied to iceberg and roman lettuce blends in multiple states underlines the importance of thorough tracebacks in identifying outbreak sources. Though the immediate outbreak risk has passed due to shelf-life expiration, heightened precautions should be taken by vulnerable populations to mitigate any future risk.
In conclusion, the dynamic nature of healthcare mandates consistent evolution, reinforced by research advancements, novel diagnostic tools, and an unwavering commitment to public health vigilance.
Source: https://www.contagionlive.com/view/top-5-infectious-disease-new-stories-week-of-december-7-13